Home / Clinical Testing / Hematologic Malignancy

Hematologic Malignancy

Most recent genetic diagnosis by using PCR and next-generation sequencing (NGS) has significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic. To help precise medicine in hematological malignancies such as leukemia, lymphoma, and multiple myeloma, MEDx has developed a variety of blood cancer tests containing panel gene assays and single target tests applied to the diagnosis and treatment of hematological proliferative disorders, and to the monitoring of recurrence and drug resistance of hematological malignancies.

• Category

• Tests

• Test Targets

• Test Methods

• Test Code

Diagnostic / Prognostic Markers

JAK2-V617F Gene Mutation Detection

JAK2-V617F Mutation

QPCR

1000034

Diagnostic / Predictive / Prognostic Markers

BCR-ABL Fusion Detection

BCR-ABL Fusion

QPCR

1000046

Diagnostic Markers

SBCMA Testing

SBCMA

ELISA

1000047

Panel Gene Detection

HemeCDx Panel Testing (Mutation Version)

505 Genes

NGS

1000044

HemeCDx Panel Testing (Full Version)

505 Genes, Containing 99 Fusions

NGS

1000045

HemeCDx Panel Testing (Fusion Version)

99 Fusion Genes

NGS

1000052

Lymphoma HEMECDx Panel Testing

188 Genes

NGS

1000060

Leukemia HEMECDx Panel Testing

158 Genes

NGS

1000061

RNAseq Fusion And Mutation Testing

Whole Transcriptome

NGS

1000072

If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.


1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D


Show of MEDx by CCTV